[go: up one dir, main page]

HK1127353A1 - Cinnamoyl-piperazine derivatives and their use as par- i antagonists - Google Patents

Cinnamoyl-piperazine derivatives and their use as par- i antagonists

Info

Publication number
HK1127353A1
HK1127353A1 HK09107160.0A HK09107160A HK1127353A1 HK 1127353 A1 HK1127353 A1 HK 1127353A1 HK 09107160 A HK09107160 A HK 09107160A HK 1127353 A1 HK1127353 A1 HK 1127353A1
Authority
HK
Hong Kong
Prior art keywords
cinnamoyl
par
antagonists
piperazine derivatives
piperazine
Prior art date
Application number
HK09107160.0A
Other languages
English (en)
Inventor
Michel Perez
Marie Lamothe
Grand Bruno Le
Robert Letienne
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of HK1127353A1 publication Critical patent/HK1127353A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HK09107160.0A 2006-06-19 2009-08-05 Cinnamoyl-piperazine derivatives and their use as par- i antagonists HK1127353A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0605419A FR2902426B1 (fr) 2006-06-19 2006-06-19 Derives de cinnamoyl-piperazine
PCT/EP2007/056086 WO2007147824A1 (en) 2006-06-19 2007-06-19 Cinnamoyl-piperazine derivatives and their use as par- i antagonists

Publications (1)

Publication Number Publication Date
HK1127353A1 true HK1127353A1 (en) 2009-09-25

Family

ID=37846050

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09107160.0A HK1127353A1 (en) 2006-06-19 2009-08-05 Cinnamoyl-piperazine derivatives and their use as par- i antagonists

Country Status (32)

Country Link
US (2) US8217046B2 (xx)
EP (1) EP2041104B1 (xx)
JP (1) JP5356222B2 (xx)
KR (1) KR101468752B1 (xx)
CN (1) CN101472907B (xx)
AR (1) AR061520A1 (xx)
AT (1) ATE478059T1 (xx)
AU (1) AU2007263051B2 (xx)
BR (1) BRPI0713132B8 (xx)
CA (1) CA2655527C (xx)
CR (1) CR10509A (xx)
DE (1) DE602007008572D1 (xx)
EC (1) ECSP099065A (xx)
ES (1) ES2349324T3 (xx)
FR (1) FR2902426B1 (xx)
GE (1) GEP20115201B (xx)
HK (1) HK1127353A1 (xx)
IL (1) IL195972A (xx)
MA (1) MA30756B1 (xx)
MX (1) MX2008016447A (xx)
MY (1) MY144461A (xx)
NO (1) NO341389B1 (xx)
NZ (1) NZ573764A (xx)
PL (1) PL2041104T3 (xx)
PT (1) PT2041104E (xx)
RU (1) RU2440997C2 (xx)
SA (1) SA07280330B1 (xx)
TN (1) TNSN08522A1 (xx)
TW (1) TWI404710B (xx)
UA (1) UA96947C2 (xx)
WO (1) WO2007147824A1 (xx)
ZA (1) ZA200900303B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3014693B1 (fr) * 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
ES2952367T3 (es) 2014-05-11 2023-10-31 Tel Hashomer Medical Res Infrastructure & Services Ltd Conjugados terapéuticos basados en PAR-1 y usos de los mismos
WO2016066789A1 (fr) * 2014-10-31 2016-05-06 Pierre Fabre Medicament Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
CN104496879A (zh) * 2015-01-13 2015-04-08 佛山市赛维斯医药科技有限公司 一种含腈基苯和二烯氟代金刚烷结构的化合物和用途
CN104496922B (zh) * 2015-01-13 2016-04-06 佛山市赛维斯医药科技有限公司 腈基苯二烯四氮唑类化合物、其制备方法和用途
CN104529860B (zh) * 2015-01-13 2016-06-01 佛山市赛维斯医药科技有限公司 一种含硝基苯和二烯氟代金刚烷结构的化合物及制备方法
CN104496924B (zh) * 2015-01-13 2016-04-13 佛山市赛维斯医药科技有限公司 卤苯二烯四氮唑类化合物、其制备方法和用途
CN105949116A (zh) * 2016-06-08 2016-09-21 青岛理工大学 酰基哌嗪类化合物及其制备方法和用途
EP3278802A1 (en) * 2016-08-04 2018-02-07 Metabolys New treatment for the non alcoholic steatohepatitis and fibrosis
RU2662308C1 (ru) * 2017-12-25 2018-07-25 Феркат Адельзянович Халиуллин Средство для лечения и профилактики тромбоза
US11497793B2 (en) 2018-05-02 2022-11-15 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating glioblastoma
FR3090317B1 (fr) * 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
WO2023055020A1 (ko) * 2021-09-29 2023-04-06 주성수 피페론구민계 화합물을 유효성분으로 포함하는 혈관질환 예방 또는 치료용 약학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61106564A (ja) * 1984-10-30 1986-05-24 Terumo Corp 不飽和脂肪酸アミド誘導体およびこれを含有する血小板凝集抑制剤
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
WO2002076965A1 (en) * 2001-03-23 2002-10-03 John Matsoukas Non peptide mimetics based on the active sequence s42fllr46 of the thrombin receptor for the treatment of thrombosis and cancer
CN1775762A (zh) * 2005-12-06 2006-05-24 山东大学 川芎嗪酰基哌嗪衍生物、制备方法和药物组合物与应用
FR2917622B1 (fr) * 2007-06-19 2009-10-23 Pierre Fabre Medicament Sa Utilisation d'un antagoniste par1 dans le traitement de la fibrillation atriale.

Also Published As

Publication number Publication date
NO20090270L (no) 2009-03-03
TW200808742A (en) 2008-02-16
KR101468752B1 (ko) 2014-12-03
TWI404710B (zh) 2013-08-11
WO2007147824A1 (en) 2007-12-27
MA30756B1 (fr) 2009-10-01
KR20090031572A (ko) 2009-03-26
DE602007008572D1 (de) 2010-09-30
FR2902426B1 (fr) 2008-09-05
RU2008152247A (ru) 2010-07-27
IL195972A (en) 2014-05-28
JP5356222B2 (ja) 2013-12-04
MY144461A (en) 2011-09-30
EP2041104A1 (en) 2009-04-01
EP2041104B1 (en) 2010-08-18
FR2902426A1 (fr) 2007-12-21
CA2655527A1 (en) 2007-12-27
NZ573764A (en) 2011-01-28
NO341389B1 (no) 2017-10-30
BRPI0713132B8 (pt) 2021-05-25
ES2349324T3 (es) 2010-12-30
GEP20115201B (en) 2011-04-11
JP2009541260A (ja) 2009-11-26
UA96947C2 (ru) 2011-12-26
CN101472907A (zh) 2009-07-01
US8217046B2 (en) 2012-07-10
PT2041104E (pt) 2010-11-08
MX2008016447A (es) 2009-01-22
US20090176803A1 (en) 2009-07-09
CA2655527C (en) 2014-12-23
IL195972A0 (en) 2009-09-01
US8513258B2 (en) 2013-08-20
SA07280330B1 (ar) 2010-10-23
BRPI0713132A2 (pt) 2012-04-17
ECSP099065A (es) 2009-02-27
AU2007263051A1 (en) 2007-12-27
US20120232097A1 (en) 2012-09-13
AR061520A1 (es) 2008-09-03
PL2041104T3 (pl) 2011-01-31
BRPI0713132B1 (pt) 2020-10-20
CN101472907B (zh) 2012-08-29
CR10509A (es) 2009-02-05
RU2440997C2 (ru) 2012-01-27
TNSN08522A1 (en) 2010-04-14
ATE478059T1 (de) 2010-09-15
ZA200900303B (en) 2009-12-30
AU2007263051B2 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
ZA200900303B (en) Cinnamoyl-piperazine derivatives and their use as par-i antagonists
HK1127604A1 (en) Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use
TWI561237B (en) Substituted dihydropyrazolones and their use
IL225521A0 (en) 1trpv antagonists and their uses
HK1203980A1 (en) Il-17ra-il-17rb antagonists and uses thereof il-17ra-il-17rb
ZA200807809B (en) Substituted chromanol derivatives and their use
IL178461A0 (en) Substituted 4-alkyl -and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
IL197232A0 (en) Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists
AP2010005202A0 (en) Isoquinolinyl and isoindolinyl derivatives as histamines-3 antagonists
AP2008004649A0 (en) Quinoline derivatives and their use as pesticides
GB0611115D0 (en) Compounds and their use
ZA200903574B (en) 2-Phenyl-6-Aminocarbonyl-Pyrimidine derivatives and their use as P2Y12 Receptor antagonists
EP2121703A4 (en) THIENOPYRIMIDIN-4-ON- AND THIENOPYRIDAZIN-7-ONDERIVATES AS MCH-RL ANTAGONISTS
IL208771A0 (en) Iminopyridine derivatives and use thereof
ZA200810565B (en) Pyrimidine derivatives and their use as pesticides
EP2077262A4 (en) IMINOPYRIDINE DERIVATIVE AND USE THEREOF
IL193118A0 (en) Soluble receptors and their use
EP2097446A4 (en) RESISTANT ANTAGONISTS AND ITS USE
ZA200810629B (en) Phenylpentadienoyl derivatives and their use as par 1 antagonists
HK1146065A1 (en) Nlrr-1 antagonists and uses thereof nlrr-1
ZA200810726B (en) Substituted N-Phenylmethyl -5-OXO-Proline-2-Amides AS P2X7-Receptor Antagonists and their methods of use
ZA200906996B (en) TRPV1 Antagonists and uses thereof
IL196823A0 (en) Tetraarylporphine derivatives and uses thereof
GB0603374D0 (en) Compounds and their use
GB0603376D0 (en) Compounds and their use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210617